Organigram Processing
About Organigram Processing
Organigram's processing division manufactures cannabis derivatives including vapes, edibles, and concentrates, leveraging BAT's strategic investment for next-generation product innovation.
Key Facts
- 1British American Tobacco invested CAD $221 million for a 19.9% stake and a product development partnership
- 2Achieved leading market share in Canadian edibles and vape categories with brands like SHRED
Latest News
Organigram Lifts 2026 Targets After Sanity Deal Completion
OGI raises financial guidance through 2026 following strategic acquisition, signaling confidence in European expansion and premium product portfolio growth.
OGI Stock Under Scrutiny as CUSIP Change Triggers Valuation Review
Organigram Holdings faces renewed investor attention following April CUSIP modification, prompting fresh analysis of fundamental metrics and market positioning.
Organigram Earnings Signal Broader Cannabis Market Stabilization
OGI's latest financial results reflect industry-wide trends as Canadian cannabis companies navigate market maturation and evolving consumer demand patterns.
Frequently Asked Questions
What is Organigram's relationship with BAT?
British American Tobacco invested in Organigram and established a Centre of Excellence collaboration to develop next-generation cannabis delivery and extraction technologies.
What Cannabis 2.0 products does Organigram make?
Organigram produces vapes, gummies, chocolates, concentrates, and infused pre-rolls under brands including SHRED, Edison, and Monjour.
Products
- Cannabis Vape Products
- Edibles and Gummies
- Cannabis Concentrates
Specialties
Company Details
- Type
- Extraction
- Location
- Moncton, NB, Canada
- Founded
- 2013
- Publicly Traded
- Yes
- Ticker
- NASDAQ:OGI